Editas Medicine (EDIT) Net Margin (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Net Margin of 332.97% for Q3 2025, up 10152932.0% year-over-year from N/an in Q3 2024, and up 77.07% quarter-over-quarter from 1452.26% in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Net Margin (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Net Margin for 11 consecutive years, with 332.97% the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Margin rose 10152932.0% year-over-year to 332.97%; the TTM figure through Sep 2025 stood at 434.48% (down 8193.0% YoY), while the FY2024 annual figure was 1937.52%, down 132279.0% from the prior year.
- Net Margin advanced to 332.97% in Q3 2025 per EDIT's latest filing, from 1452.26% in the prior quarter.
- Across five years, Net Margin topped out at 36.94% in Q4 2023 and bottomed at 3785952.38% in Q3 2022.
- Historically, Net Margin has averaged 213064.53% across 5 years, with a median of 2489.11% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin plunged 378486314 bps — and 2023, when it soared 378346327 bps.
- Editas Medicine's Net Margin stood at 270.41% in 2021, then slumped by 227 bps to 885.33% in 2022, then surged by 96 bps to 36.94% in 2023, then sank by 303 bps to 148.98% in 2024, then tumbled by 123 bps to 332.97% in 2025.
- Business Quant data shows EDIT's Net Margin at 332.97% in Q3 2025, 1452.26% in Q2 2025, and 1692.85% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -332.97% |
| Jun 30, 2025 | -1,438.71% |
| Mar 31, 2025 | -1,624.37% |
| Dec 31, 2024 | -148.32% |
| Sep 30, 2024 | -101,862.30% |
| Jun 30, 2024 | -13,178.56% |
| Mar 31, 2024 | -5,458.68% |
| Dec 31, 2023 | -31.41% |
| Sep 30, 2023 | -843.68% |
| Jun 30, 2023 | -1,395.32% |
| Mar 31, 2023 | -481.70% |
| Dec 31, 2022 | -929.22% |
| Sep 30, 2022 | -132,683.33% |
| Jun 30, 2022 | -843.89% |
| Mar 31, 2022 | -742.59% |
| Dec 31, 2021 | -332.30% |
| Sep 30, 2021 | -630.97% |
| Jun 30, 2021 | -14,579.16% |
| Mar 31, 2021 | -873.20% |
| Dec 31, 2020 | -547.32% |